Actualizado 01/09/2010 11:33
- Comunicado -

DAIICHI SANKYO Announces Enrollment in the Two Largest Single Phase III Trials so far for the Prevention of Stroke in AF

[7] http://www.daiichi-sankyo.de/_uploads/media/2199_PI_DAIICHI%.... Last accessed 13.08.2010.

[8] The HOKUSAI VTE trial: http://clinicaltrials.gov/ct2/show/NCT00.... Last accessed 13.08.2010.

[9] http://www.daiichisankyo.com/news/detail.... Last accessed 23.07.2010

(Due to the length of the above URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

    
    CONTACT:
    Dr. Michaela Paudler-Debus
    Vice Director
    Head of Product PR
    Corporate Communications and Public Affairs
    Phone +49(0)89-78-08-685
    michaela.paudler-debus@daiichi-sankyo.eu
    Dr. Felix Münzel
    Vice Director
    Medical and Scientific Affairs CV
    Phone +49(0)89-78-08-471
    felix.muenzel@daiichi-sankyo.eu

CONTACT: Dr. Michaela Paudler-Debus, Vice Director, Head of Product PR, Corporate Communications and Public Affairs, Phone +49(0)89-78-08-685, michaela.paudler-debus@daiichi-sankyo.eu; Dr. Felix Münzel, Vice Director, Medical and Scientific Affairs CV, Phone +49(0)89-78-08-471, felix.muenzel@daiichi-sankyo.eu

Contenido patrocinado